Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic
Decoy Therapeutics has partnered with hVIVO, a global leader in human challenge trials, to advance its lead D-MAV antiviral candidate into Phase 1 and Phase 2a clinical studies. The collaboration leverages hVIVO’s expertise in translational modeling, regulatory strategy, and CMC consulting to prepare for IND/CTA filings with the EMA, MHRA, and FDA.
Key figures
- Drug Name
- D-MAV
- Phase Of Trial
- Phase 1 and Phase 2a
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.